Press Releases


Latest News


Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
Jan 9, 2014 | General Releases

Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress
Oct 2, 2013 | General Releases

Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease
Jun 18, 2013 | General Releases

Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Jun 10, 2013 | General Releases

Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCL ER) Program
Apr 22, 2013 | General Releases

Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from Its Nurelin™ Program at American Academy of Neurology Conference
Mar 20, 2013 | General Releases

Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease
Nov 13, 2012 | General Releases

Adamas Pharmaceuticals Presents Update On NurelinTM Program At Cambridge Healthtech Institute’s Parkinson’s Conference.
Jun 4, 2012 | General Releases

Adamas Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For ARIMENDATM
May 15, 2012 | General Releases

Adamas Pharmaceuticals Initiates A Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease
Sep 28, 2011 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10